Form 4: Inscobee Inc. Reports Conversion of Convertible Notes into Apimeds Pharmaceuticals US, Inc. Common Stock Following Qualified Financing
SEC Form 4
Inscobee Inc. reports the conversion of convertible promissory notes into common stock of Apimeds Pharmaceuticals US, Inc. following a qualified financing event.
Summary
- Inscobee Inc., a reporting person, filed a Form 4 detailing changes in beneficial ownership of Apimeds Pharmaceuticals US, Inc. (APUS) common stock.
- The filing indicates that on May 12, 2025, a qualified financing was completed, triggering the conversion of outstanding convertible promissory notes into common stock.
- The notes, issued to Apimeds Inc. and Inscobee Inc., converted at a price of $2.60 per share.
- The conversion included the August 2021 Note ($400,000 principal plus $73,205 interest) converting into 182,002 shares, the March 2022 Note ($160,000 principal plus $24,833 interest) converting into 71,090 shares, and the June 2022 Note ($100,000 principal plus $14,507 interest) converting into 44,041 shares.
- Inscobee Inc. also purchased 500,000 shares of common stock at $4 per share.
- Following these transactions, Inscobee Inc. directly owns 2,028,657 shares and indirectly owns 4,387,708 shares through its wholly-owned subsidiary, Apimeds Inc.
Sentiment
Score: 7
Explanation: The sentiment is moderately positive. The completion of a qualified financing and conversion of debt to equity are generally positive signs, but the lack of details about the financing and the company's overall performance limits a higher score.
Positives
- The completion of a qualified financing is generally a positive event for the company.
- Conversion of debt into equity strengthens the company's balance sheet.
- Inscobee Inc.'s increased equity stake demonstrates continued investment in Apimeds Pharmaceuticals US, Inc.
Risks
- The document does not provide information about the nature of the qualified financing, so the specific terms and potential dilution are unknown.
- The document does not provide information about the performance of Apimeds Pharmaceuticals US, Inc.
Future Outlook
The document does not contain specific forward-looking statements beyond the maturity date of the notes if a qualified offering does not occur.
Industry Context
Form 4 filings are standard disclosures for insiders and large shareholders, providing transparency into their transactions. The conversion of debt into equity following a qualified financing is a common occurrence, often signaling a company's readiness for further growth or a public listing.
Stakeholder Impact
- Shareholders may experience dilution due to the conversion of notes into common stock.
- The company's balance sheet is strengthened by the conversion of debt into equity.
- The qualified financing may enable the company to pursue growth initiatives.
Key Dates
| Date | Description |
|---|---|
| August 30, 2021 | Apimeds Pharmaceuticals US, Inc. issued a convertible promissory note to Apimeds Inc. |
| March 21, 2022 | Apimeds Pharmaceuticals US, Inc. issued a convertible promissory note to Apimeds Inc. |
| June 3, 2022 | Apimeds Pharmaceuticals US, Inc. issued a convertible promissory note to Inscobee Inc. |
| May 12, 2025 | Qualified Financing completed, convertible notes converted into common stock. |
| May 14, 2025 | Date of the Form 4 filing. |
| December 31, 2026 | Maturity date of the convertible promissory notes if a Qualified Offering does not occur earlier. |
Keywords
Apimeds Pharmaceuticals US, Inc., Inscobee Inc., convertible note, qualified financing, common stock, beneficial ownership, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.